drugset / Trial / NCT03614650
Immunotherapy Treating GI Cancer
NaSingle-groupOpen-labelTreatment
Summary
The primary objectives are to evaluate the safety and efficacy of infusion of autologous gastro-intestinal (GI) cancer antigen-specific engineered immune effector cells (EIE).
Timeline
- Start
- 2025-07-01
- Primary completion
- 2028-06-30
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Engineered immune effector cells | Cell therapy | — | Intravenous |